Lifeboat Foundation

I posted about this a while back, as a treatment. I’m glad people are catching up.

Some doctors are now trying to deliver 100% oxygen to COVID patients in decompression chambers long used to treat divers with the bends.

As a New York University medical researcher who works once a week in an emergency room, Dr. David Lee had the luxury of time to think like a scientist while also treating coronavirus patients whose lungs kept giving out. In every case, he saw the same thing: Their blood was starved of oxygen.

Continue reading “Doctors try pressurized oxygen chambers in COVID fight” »

Summary: Activating p38gamma, a naturally protective enzyme in the brain, may help to prevent the development of Alzheimer’s disease symptoms. Researchers showed the naturally protective effects of p38gamma could be harnessed to improve memory in the later stages of Alzheimer’s disease.

Source: Macquarie University

Continue reading “New Hope as Dementia Therapy Reverses Memory Loss” »

The agreement with Sanofi and GlaxoSmithKelin is the government’s second in less than two weeks for 100 million doses of vaccine.

The first-of-its-kind, randomized, placebo-controlled, phase 1/2a trial will assess patients hospitalized at Florida and South Dakota institutions.

Researchers announce the first patient has been dosed in a trial testing remestemcel-L, a stem cell therapy, in severe COVID-19 patients on ventilators.

Testing of an experimental COVID-19 stem cell therapy has begun in the US. The therapy has been developed to treat hospitalised COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators. A total of 300 are expected to be recruited into the randomised, placebo-controlled trial.

ENCODE Project’s third phase offers new insights into the organization and regulation of our genes and genome.

The Encyclopedia of DNA Elements (ENCODE) Project is a worldwide effort to understand how the human genome functions. With the completion of its latest phase, the ENCODE Project has added millions of candidate DNA “switches” from the human and mouse genomes that appear to regulate when and where genes are turned on, and a new registry that assigns a portion of these DNA switches to useful biological categories. The project also offers new visualization tools to assist in the use of ENCODE’s large datasets.

The project’s latest results were published in Nature, accompanied by 13 additional in-depth studies published in other major journals. ENCODE is funded by the National Human Genome Research Institute, part of the National Institutes of Health.

More from 2020 “The Movie”

Chinese government-linked hackers targeted biotech company Moderna Inc, a leading U.S.-based coronavirus vaccine research developer, earlier this year in a bid to steal valuable data, according to a U.S. security official tracking Chinese hacking activity.

WASHINGTON (Reuters) — Chinese government-linked hackers targeted biotech company Moderna Inc, a leading U.S.-based coronavirus vaccine research developer, earlier this year in a bid to steal valuable data, according to a U.S. security official tracking Chinese hacking activity.

(Reuters) — AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries with which it has struck supply agreements, a senior executive told Reuters.

CRISPR-Cas9 base editors comprise RNA-guided Cas proteins fused to an enzyme that can deaminate a DNA nucleoside. No natural enzyme deaminates adenine in DNA, and so a breakthrough came when a natural transfer RNA deaminase was fused to Cas9 and evolved to give an adenine base editor (ABE) that works on DNA. Further evolution provided the enzyme ABE8e, which catalyzes deamination more than 1000 times faster than early ABEs. Lapinaite et al. now present a 3.2-angstrom resolution structure of ABE8e bound to DNA in which the target adenine is replaced with an analog designed to trap the catalytic conformation. The structure, together with kinetic data comparing ABE8e to earlier ABEs, explains how ABE8e edits DNA bases and could inform future base-editor design.

Science, this issue p. 566

CRISPR-Cas–guided base editors convert A•T to G•C, or C•G to T•A, in cellular DNA for precision genome editing. To understand the molecular basis for DNA adenosine deamination by adenine base editors (ABEs), we determined a 3.2-angstrom resolution cryo–electron microscopy structure of ABE8e in a substrate-bound state in which the deaminase domain engages DNA exposed within the CRISPR-Cas9 R-loop complex. Kinetic and structural data suggest that ABE8e catalyzes DNA deamination up to ~1100-fold faster than earlier ABEs because of mutations that stabilize DNA substrates in a constrained, transfer RNA–like conformation. Furthermore, ABE8e’s accelerated DNA deamination suggests a previously unobserved transient DNA melting that may occur during double-stranded DNA surveillance by CRISPR-Cas9. These results explain ABE8e-mediated base-editing outcomes and inform the future design of base editors.